Kaiser Health News, February 9, 2017. For every cancer patient who wins the lottery, there are many others who get little to no benefit from the latest drugs.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Trump’s Proposed Changes Gut FDA While Targeting Drug Prices
Legal Reader, February 2, 2017. In a study published on the JAMA Network, Dr. Zuckerman and her co-author, Tracy Rupp, looked at certain new – and expensive – cancer drugs. They found that many of these drugs failed to improve patient quality of life or extend patient life.
Read More »Trump Calls for Lower Drug Prices, Fewer Regulations in Meeting with Pharmaceutical Executives
The Washington Post, January 31, 2017. President Trump met with leaders of some of the world’s biggest pharmaceutical companies Tuesday and emphasized the need to lower “astronomical” drug prices, decrease regulations and bring more drug manufacturing into the United States. “There are many empty positions at the FDA,” said Diana Zuckerman, president of the National Center for Health Research. The recently enacted 21st Century Cures law provided for additional hiring authority. “But with the hiring freeze, will they be able to hire anyone?” she asked.
Read More »Trump Vows to Ease Rules for Drug Makers, But Again Zeros in on Prices
The New York Times, January 31, 2017. President Trump promised some of the nation’s top drug company executives in a meeting at the White House on Tuesday that he would slash regulations at the Food and Drug Administration and make it easier for them to manufacture products in the United States. “Streamlining drug approvals sounds good, but the agency has already weakened approval standards and patients are paying the price — hugely expensive drugs that don’t even work,” said Diana Zuckerman, president of the National Center for Health Research, a Washington research group that advocates strong safety and efficacy standards. She recently studied expensive new cancer drugs and found that many did not help patients feel better or live longer.
Read More »ACA Repeal Talk Sparks Fears Among Those with Pre-existing Conditions
The Times-Standard, January 28, 2017. The possible repeal of the Affordable Care Act reintroduces a fear among people with pre-existing conditions of maintaining health insurance. Under the ACA, pre-existing conditions were not counted against applicants seeking coverage through the state’s exchange, Covered California, but that could change if ACA is repealed and replaced under the Trump administration.
Read More »